DE69633272D1 - Methoden zur krebskontrolle und -behandlung - Google Patents

Methoden zur krebskontrolle und -behandlung

Info

Publication number
DE69633272D1
DE69633272D1 DE69633272T DE69633272T DE69633272D1 DE 69633272 D1 DE69633272 D1 DE 69633272D1 DE 69633272 T DE69633272 T DE 69633272T DE 69633272 T DE69633272 T DE 69633272T DE 69633272 D1 DE69633272 D1 DE 69633272D1
Authority
DE
Germany
Prior art keywords
treatment
methods
cancer control
expression
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69633272T
Other languages
English (en)
Other versions
DE69633272T2 (de
Inventor
Kei Fujinaga
Koichi Yoshida
Fumihiro Higashino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Bio Inc
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Publication of DE69633272D1 publication Critical patent/DE69633272D1/de
Application granted granted Critical
Publication of DE69633272T2 publication Critical patent/DE69633272T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
DE69633272T 1995-02-08 1996-01-09 Methoden zur Krebsbehandlung und -kontrolle Expired - Fee Related DE69633272T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017395 1995-02-08
JP2017395 1995-02-08
PCT/JP1996/000016 WO1996024379A1 (fr) 1995-02-08 1996-01-09 Traitement du cancer

Publications (2)

Publication Number Publication Date
DE69633272D1 true DE69633272D1 (de) 2004-10-07
DE69633272T2 DE69633272T2 (de) 2005-09-08

Family

ID=12019792

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633272T Expired - Fee Related DE69633272T2 (de) 1995-02-08 1996-01-09 Methoden zur Krebsbehandlung und -kontrolle

Country Status (7)

Country Link
US (3) US6096542A (de)
EP (2) EP0808630B1 (de)
JP (1) JP3844501B2 (de)
AT (1) ATE274922T1 (de)
AU (1) AU4357396A (de)
DE (1) DE69633272T2 (de)
WO (1) WO1996024379A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1084969A (ja) * 1996-09-19 1998-04-07 Chemo Sero Therapeut Res Inst ヘモフィルス・パラガリナルム由来新規ポリペプチド及びその製法
US6248351B1 (en) 1997-01-10 2001-06-19 Board Of Regents,The University Of Texas System Human PEA3 is a tumor suppressor for cancer cells
CA2402816A1 (en) * 2000-03-20 2001-09-27 Mcgill University Antisense nucleic acid molecules targeted to type i collagenase (mmp-1) for inhibition of melanoma invasion
WO2002064165A1 (fr) * 2001-02-13 2002-08-22 Hisamitsu Pharmaceutical Co., Inc. Inhibiteurs de la proliferation cellulaire comprenant un facteur de transcription ets ou un gene codant ce dernier
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
LT2484375T (lt) 2006-09-26 2018-07-10 Infectious Disease Research Institute Vakcinos kompozicija, turinti sintetinio adjuvanto
BRPI1011072B1 (pt) 2009-06-05 2021-09-28 Infectious Disease Research Institute Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
PL2850431T3 (pl) 2012-05-16 2018-09-28 Immune Design Corp. Szczepionki przeciwko HSV-2
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
MX2016008640A (es) 2013-12-31 2016-10-07 Infectious Disease Res Inst Formulaciones de vacuna de vial unico.
GB201410686D0 (en) * 2014-06-16 2014-07-30 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3463300A1 (de) 2016-06-01 2019-04-10 Infectious Disease Research Institute Nanoalum-partikel mit einem leimungsmittel
WO2019051149A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
KR20220125149A (ko) 2019-05-25 2022-09-14 액세스 투 어드밴스드 헬스 인스티튜트 애주번트 백신 에멀션을 분무 건조시키기 위한 조성물 및 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05328975A (ja) * 1992-06-02 1993-12-14 Takara Shuzo Co Ltd Ｅ１ａ−ｆ遺伝子
JPH07509133A (ja) * 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US5872242A (en) * 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
WO1994016057A1 (en) * 1992-12-31 1994-07-21 Dana-Farber Cancer Institute, Inc. Enhancer sequence for modulating expression in epithelial cells
CA2175824A1 (en) * 1993-11-12 1995-05-18 Kenneth G. Draper Method and reagent for treatment of arthritic conditions
US5552390A (en) * 1993-12-09 1996-09-03 The Board Of Regents Of The University Of Nebraska Phosphorothioate inhibitors of metastatic breast cancer
WO1996018736A2 (en) * 1994-12-13 1996-06-20 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
JP2002543854A (ja) * 1999-05-14 2002-12-24 カイロン コーポレイション 癌におけるｅｔｓドメインタンパク質の発現

Also Published As

Publication number Publication date
US6096542A (en) 2000-08-01
EP0808630A4 (de) 2000-09-27
EP1484067A2 (de) 2004-12-08
EP0808630A1 (de) 1997-11-26
AU4357396A (en) 1996-08-27
EP0808630B1 (de) 2004-09-01
US20030087862A1 (en) 2003-05-08
DE69633272T2 (de) 2005-09-08
US7070931B2 (en) 2006-07-04
US6528310B1 (en) 2003-03-04
WO1996024379A1 (fr) 1996-08-15
JP3844501B2 (ja) 2006-11-15
EP1484067A3 (de) 2005-03-02
ATE274922T1 (de) 2004-09-15

Similar Documents

Publication Publication Date Title
DE69633272D1 (de) Methoden zur krebskontrolle und -behandlung
AU7074698A (en) Detection and modulation of the iaps and naip for the diagnosis and treatment ofproliferative disease
TR199701462T1 (xx) DNA Dizisi ve bununla kodlanm�� meme'ye �zel g���s kanseri proteini.
DE59609222D1 (de) Amperometrischer Biosensor
ATE317435T1 (de) Prostataspezifisches membranes antigen und seine anwendungen
ATE433498T1 (de) Detektion von neoplasien durch speichelanalyse
ATE280160T1 (de) Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität
ES2117855T3 (es) Proteina del ciclo celular de mamifero.
NO970514D0 (no) Bakteriell produksjon av hydrofobiske polypeptider
DE69332642T2 (de) Methoden zur detektion von mikrometastasen bei prostata-krebs
DE60238493D1 (de) Is von seltenen zellen verwendete markierte zellen
DE19622397B8 (de) Elektrische Vorrichtung als Sauerstoffkonzentrationssensor
AU5996996A (en) Al/fe-treatment of a protein solution, followed by membrane concentration
AP9901607A0 (en) Method and apparatus for continuous flow isoelectric focusing for
ATE225859T1 (de) Nachweis von antibiotikumresistenzen in mikroorganismen
ATE122723T1 (de) Retinoblastoma-genprodukt-antikörper und deren verwendungen.
EP0974658A4 (de) SONDEN ZUM NACHWEIS VON DURCH -i(STREPTOCOCCUS PYOGENES) HERVORGERUFENEN INFEKTIONEN
SE9603344D0 (sv) Method and apparatus for detecting substances
WO2000015175A3 (en) Use as an active substance of molecules binding to beta-1-integrin with the capacity to kill cells
MX9706654A (es) Ensayo de flujo lateral de lectura directa para elementos a analizar pequeños.
FI904941A (fi) Foerfarande foer effektivering av styrning av hissdoerrar.
WO2003092587A3 (en) Modulation of bacterial membrane permeability
IT1311508B1 (it) Dispositivo per la ricerca di microrganismi.
DK0792348T3 (da) Svampen Gliocladium catenulatum til biologisk bekæmpelse af plantesygdomme
UA25582C2 (uk) Засіб для лікування гематоцитопенічних реакцій теплокровних організмів

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee